DBV Technologies Reports
December 31, 2015, Cash Position


Cash and cash equivalents
DBV's cash and cash equivalents amounted to €324.0 million as of December 31, 2015, compared to €332.2 million as of September 30, 2015.

Number of outstanding shares
As of December 31, 2015, DBV's number of outstanding shares was 24,205,129 ordinary shares, compared to 19,160,661 ordinary shares outstanding as of December 31, 2014.

About DBV Technologies
DBV Technologies is developing Viaskin®, an innovative new approach to the treatment of allergies – a major public health issue that has been increasing in prevalence. DBV Technologies, incorporated in France in 2002, has developed a proprietary, patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus lowering the risk of a systemic, allergic reaction in the event of accidental exposure. DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. DBV Technologies has designed two products candidates: Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation and Breakthrough Therapy designation from the U.S. Food and Drug Administration.

DBV Technologies shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and on the Nasdaq Stock Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com

Forward Looking Statements
This press release contains forward-looking statements that are not promises or guarantees and involve substantial risks and uncertainties. The Company's product candidates have not been approved for sale in any jurisdiction. Among the factors that could cause actual results to differ materially from those described or projected herein are uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, the risk that historical preclinical results may not be predictive of future clinical trial results, and the risk that historical clinical trial results may not be predictive of future trial results. A further list and description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers, the Company's Securities and Exchange Commission filings and reports, including in the Company’s Annual Report
on Form 20-F for the year ended December 31, 2014 and future filings and reports by the Company. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release, whether as a result of new information, future events or circumstances or otherwise.

DBV Technologies Contacts

Nathalie Donne  
Director, Corporate Communication & Business Development  
Tel. : +33(0)1 55 42 78 72  
nathalie.donne@dbv-technologies.com

Susanna Mesa  
VP Finance, US Investor Relations & Strategy  
Tel. : +1 212-271-0861  
susanna.mesa@dbv-technologies.com

DBV Technologies Media Contacts US & Europe

Marion Janic  
Rooney & Associates  
Tel. : +1-212-223-4017  
mjanic@rooneyco.com

Caroline Carmagnol  
Alize RP – Relation Presse  
Tel. : +33(0)6 64 18 99 59  
caroline@alizerp.com